Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
GSK plc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 50.01 · gapped above the open, then crossed back over prior close. High/low 50.22 at 4:30 am ET, 49.71 at 9:30 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of GSK revenue | Skew |
|---|---|---|---|
| SPROSpero Therapeutics, Inc. | 1.00% | <0.01% | 658× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Non-cash royalty revenue related to our agreement with GSK increased $7.6 million, to approximately $108.6 million for the year ended December 31, 2025, from $101.0 million for the year ended December 31, 2024, due to increased net sales of GSK's vaccines containing our QS-21 STIMULON adjuvant.”
FILING10-K0001193125-26-108632cik 0001098972disclosed by AGEN
“Our portfolio includes nivisnebart (formerly AL101/GSK4527226), an investigational PGRN-elevating antibody that has completed enrollment in a placebo-controlled, double-blinded Phase 2 study in early Alzheimer's disease under our July 2021 Collaboration and License Agreement (GSK Agreement) with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK).”
FILING10-K0001193125-26-071593cik 0001653087disclosed by ALEC
“We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.”
FILING10-K0001193125-26-088290cik 0001370053disclosed by ANAB
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.”
FILING10-K0001408075-26-000009cik 0001408075disclosed by GPK
“Currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.”
FILING10-K0001193125-26-071776cik 0001080014disclosed by INVA
“In addition to the milestones described above, GSK is obligated to pay royalties to us on annual net sales of GSK Licensed Products in the GSK Territory. Such royalties are 1% for annual sales up to $750.0 million each year and range from high single-digit percentages on annual net sales above $750.0 million each year to low double-digit percentages on annual net sales above $1,000.0 million each year.”
$668,020 relationship658× more of SPRO’s book than GSK’s
basisSPRO fy2025 · closed 2025-12 $67MGSK fy2025 · closed 2025-12 $43.9B
FILING10-K0001193125-26-126192cik 0001701108disclosed by SPRO
“We received the $225.0 million from GSK in June 2025.”
FILING10-K0001104659-26-033077cik 0001583107disclosed by TBPH
“Under the GSK Agreement, we agreed, on a non-exclusive basis, to provide GSK with certain of our products and services, including licensed data, sequencing, clinical trial matching, organoid modeling services, algorithm development, and others.”
FILING10-K0000950170-25-025603cik 0001717115disclosed by TEM
“Revenue for the year ended December 31, 2025 was $42.7 million, and was earned under the GSK Collaboration Agreement.”
FILING10-K0001193125-26-073472cik 0001631574disclosed by WVE
“Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs.”
FILING10-K0001193125-26-071776cik 0001080014disclosed by INVA
“GSK supplied niraparib for use in the collaboration, at no cost to us.”
FILING10-K0001725160-26-000014cik 0001725160disclosed by ZNTL
“To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").”
FILING10-K0001200375-26-000006cik 0001200375disclosed by CDXS
“Botox Therapeutic is marketed by GSK in Japan.”
FILING10-K0001551152-26-000008cik 0001551152disclosed by ABBV
“Under the terms of this agreement, we granted GSK an exclusive, worldwide license under certain patents and know-how to research, develop, manufacture and commercialize certain compounds and products directed to the Collaboration Targets.”
FILING10-K0001736730-26-000016cik 0001736730disclosed by CAMP
“For example, in the past we have manufactured clinical trial material for AstraZeneca, Biogen, GSK, Roche, and Novartis and commercial drug supply for Biogen.”
FILING10-K0000874015-26-000115cik 0000874015disclosed by IONS
“In March 2009, we entered into a license agreement with GSK, which was amended in April 2009, in order to secure the exclusive rights to patents and patent applications covering NAV Technology that GSK had previously licensed from Penn (subject to certain rights retained by GSK and Penn).”
FILING10-K0000950170-25-038770cik 0001590877disclosed by RGNX
“In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target PVRIG, including the antibody GSK4381562 (the "Licensed Antibodies").”
FILING10-K0001104659-26-025308cik 0001512762disclosed by CHRS
“In March 2023, we and GSK plc ("GSK") entered into a Research License Agreement (the "GSK License Agreement") which superseded and replaced our prior agreements with GSK.”
FILING10-K0001104659-26-023804cik 0001819576disclosed by LQDA
“We have demonstrated strong success in this market, most notably through hardware and models we've trained for G42, MBZUAI, GlaxoSmithKline, Sandia National Laboratory, the U.S. Department of Defense, and other training customers.”
FILINGS-1/A0001628280-26-033143cik 0002021728disclosed by CBRS
“license agreement with Tesaro, a company later acquired by GSK, pursuant to which we obtained an exclusive sublicense under certain patents and know-how of GSK (including such patents and know-how licensed from Merck, Sharp & Dohme Corp.”
FILING10-K0001704292-26-000015cik 0001704292disclosed by ZLAB
Watchlist prices, news filtered to it, and its next report on your desk.
GSK plc has 14 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either GSK plc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
GSK (GSK plc) has 14 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LQDA −1.40%, in healthcare.